Pacific Biosciences
PACB
148 hedge funds and large institutions have $607M invested in Pacific Biosciences in 2019 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 49 increasing their positions, 50 reducing their positions, and 24 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
2% less repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 50
4% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 24
1% less funds holding
Funds holding: 150 → 148 (-2)
4.82% less ownership
Funds ownership: 81.67% → 76.85% (-4.8%)
20% less capital invested
Capital invested by funds: $756M → $607M (-$150M)
54% less call options, than puts
Call options by funds: $712K | Put options by funds: $1.56M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$13.3M |
| 2 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$8.12M |
| 3 |
Millennium Management
New York
|
+$6.93M |
| 4 |
VI
Versor Investments
New York
|
+$5.54M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$5.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$24.6M |
| 2 |
WIC
Water Island Capital
New York
|
-$17.7M |
| 3 |
Goldman Sachs
New York
|
-$11.6M |
| 4 |
LP
LMR Partners
London,
United Kingdom
|
-$6.94M |
| 5 |
Caisse de Depot et Placement du Quebec (CDPQ)
Montreal,
Quebec, Canada
|
-$5.23M |
PACB Hedge Fund Activity: Q3 2019 in Review
148 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q3 2019, worth a combined $607M — down 20% from $756M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of PACB and 23 opened new positions — a net loss of 1 holder — while 50 trimmed existing stakes and 49 added.
The largest buyer was Bellevue Group, opening a new position worth an estimated $13.3M. The largest seller was Citadel Advisors, cutting an estimated $24.6M.
- 148 institutional investors held Pacific Biosciences (PACB) as of Q3 2019, down from 150 in Q2 2019.
- Funds reported $607M of Pacific Biosciences stock for Q3 2019, down 20% quarter-over-quarter.
- 23 funds opened new Pacific Biosciences positions in Q3 2019 and 24 closed out, a net change of -1 holder.
- The largest Pacific Biosciences buyer in Q3 2019 was Bellevue Group, an estimated $13.3M added.
- The largest Pacific Biosciences seller in Q3 2019 was Citadel Advisors, an estimated $24.6M sold.
Based on aggregated 13F filings for Q3 2019.